Literature DB >> 9576972

Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence.

F Cosman1, R Lindsay.   

Abstract

Most of the data on the anabolic effect of PTH have been obtained with hPTH(1-34). Studies have shown a marked increment in spinal bone mass. Most recently we have shown that PTH and estrogen can be given together where there is increased total bone mineral and no loss of bone at any skeletal site. We have also shown the first reduction in vertebral deformity incidence due to PTH treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576972     DOI: 10.1007/s002239900464

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

Review 1.  Stemming bone loss by suppressing apoptosis.

Authors:  J M Hock
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 2.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 3.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

4.  Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.

Authors:  M R Ehlers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

5.  Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats.

Authors:  Yankel Gabet; David Kohavi; Ralph Müller; Michael Chorev; Itai Bab
Journal:  Osteoporos Int       Date:  2005-04-06       Impact factor: 4.507

6.  Osteoporotic fracture and parathyroid hormone.

Authors:  Nabanita S Datta
Journal:  World J Orthop       Date:  2011-08-18

Review 7.  Therapeutic potential of parathyroid hormone.

Authors:  Felicia Cosman; Robert Lindsay
Journal:  Curr Osteoporos Rep       Date:  2004-03       Impact factor: 5.096

8.  Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.

Authors:  Robert S Weinstein; Robert L Jilka; Maria Almeida; Paula K Roberson; Stavros C Manolagas
Journal:  Endocrinology       Date:  2010-04-21       Impact factor: 4.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.